FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference

Rhea-AI Summary

FibroGen, Inc. (NASDAQ: FGEN) will have CEO Enrique Conterno participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Conference on December 8 at 1:05 PM Eastern Time. Investors can access a live audio webcast on the company's Investors webpage, with a replay available for 30 days. FibroGen focuses on developing first-in-class therapeutics, including treatments for idiopathic pulmonary fibrosis, pancreatic cancer, and anemia. Notably, Roxadustat is approved in multiple countries for CKD anemia and is in advanced trials for related conditions.

SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Conference on December 8, at 1:05 PM Eastern Time.

A live audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investors webpage at www.fibrogen.com. The replay will be available for approximately 30 days.

About FibroGen
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), metastatic pancreatic cancer, and Duchenne muscular dystrophy (DMD). Roxadustat (爱瑞卓^®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and not on dialysis. Roxadustat is in Phase 3 clinical development in the U.S. and Europe for anemia associated with myelodysplastic syndromes (MDS), and in Phase 3 clinical development in China for treatment of chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com. 

Contact:
FibroGen, Inc.

Investors:
Michael Tung, M.D.
Corporate Strategy / Investor Relations
mtung@fibrogen.com

Media:
Meichiel Keenan
Investor Relations and Corporate Communications
mkeenan@fibrogen.com

FAQ

When is Enrique Conterno speaking at the Bank of America 2022 Biotech SMID Cap Virtual Conference?

Enrique Conterno will speak on December 8 at 1:05 PM Eastern Time.

Where can I watch the FibroGen conference webcast?

The webcast can be viewed on the 'Events & Presentations' section of the FibroGen Investors webpage.

What is the focus of FibroGen's therapeutic development?

FibroGen focuses on developing first-in-class therapeutics for various conditions, including cancer and anemia.

What is Roxadustat and where is it approved?

Roxadustat is an anemia treatment approved in China, Europe, Japan, and other regions for chronic kidney disease.

Which diseases is Pamrevlumab targeting in clinical trials?

Pamrevlumab is in trials for idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy.